Vnitr Lek 2005, 51(10):1120-1125

Prothrombotic status as part of metabolic syndrome

A. Remková

I. interná klinika Lekárskej fakulty UK, Bratislava, Slovenská republika, prednosta prof. MUDr. Anna Remková, Ph.D., DrSc.

Metabolic syndrome is associated with prothrombotic status, which participates in the development of atherothrombotic complications. Nevertheless, dysregulation of haemostasis is of a complex nature and involves endothel activation, hyperactivity of thrombocytes, hypercoagulability and hypofibrinolysis. Increased expression of type 1 plasminogen activator inhibitor with subsequent hypofibrinolysis is the main haemostatic disorder in relation to insulin resistance and is currently considered as a part of a set of abnormalities within the scope of the metabolic syndrome. The mechanism which leads to prothrombotic status in metabolic syndrome is multifactorial. Recently, great significance has been attributed to cytokine-mediated low-degree inflammation which is closely linked to the metabolic syndrome and participates on dysregulation of haemostasis. Body weight reduction, physical activity and adequate pharmacological processes are effective means reducing the prothrombotic status impact in metabolic syndrome. Angiotensin converting enzyme inhibitors, which can favourably influence even haemostatic mechanisms according to recent data, serve as an example. The treatment of prothrombotic status in the metabolic syndrome could result in the decrease of atherothrombotic events, which are characteristic complications of metabolic syndrome.

Keywords: insulin resistance; hypertension; endothel; thrombocytes; fibrinolysis

Received: January 12, 2005; Accepted: March 14, 2005; Published: October 1, 2005  Show citation